Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.
-
Upload
allen-powell -
Category
Documents
-
view
220 -
download
0
Transcript of Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.
![Page 1: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/1.jpg)
Pediatric Anxiety:Current and Future Approaches to
Therapeutics
Daniel S. Pine, MDDaniel S. Pine, MD
![Page 2: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/2.jpg)
Disclosures
Sources of Research SupportSources of Research Support
National Institute of Mental HealthNational Institute of Mental Health
Paid Editorial Relationship Am J Psychiatry– Deputy Editor
Consulting Relationships None
Stock Equity (>$10,000)None
Speaker’s BureauNone
Role in pharmacology researchRole in pharmacology research
FDA Committee & Black Box VoteFDA Committee & Black Box Vote
““Off-Label” useOff-Label” use
My perspectiveMy perspective
![Page 3: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/3.jpg)
Outline & Objectives Classifying Pediatric Anxiety & MDDClassifying Pediatric Anxiety & MDD
Broad categorization schemeBroad categorization scheme Outcome & treatment implicationsOutcome & treatment implications
Current Treatments for Pediatric AnxietyCurrent Treatments for Pediatric Anxiety
Going Beyond SSRIs & CBT?Going Beyond SSRIs & CBT? Underlying neurobiologyUnderlying neurobiology Other treatments?Other treatments?
![Page 4: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/4.jpg)
OCDAssociations with tics, ADHD
Basal ganglia dysfunction, PANDAS Leckman, Peterson, Rosenberg, Swedo, others
PTSDLongitudinal associations with wide array of disorders
HPA axis dysfunctionDeBellis, Heim, Nemeroff, Pynoos, others
Social Anxiety, GAD, Separation Anxiety, [Phobias]
Considered as a group in most major treatment studiesBiederman, Kendal, Kessler, Pine, Rosenbaum, Weissman, others
Specific Association with MDD?Particularly GAD
Categorizing Childhood Anxiety
![Page 5: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/5.jpg)
Longitudinal Data
Clinic-basedClinic-based
Family-basedFamily-based
Community-basedCommunity-based
Sub-clinical PrecursorsSub-clinical Precursors
![Page 6: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/6.jpg)
Any Adolescent Anxiety Disorder & Any Adult Mood/Anxiety Disorder
Disorder as Adults?Disorder as Adults?
Disorder asDisorder as
Adolescents?Adolescents?NoNo YesYes
NoNo 390390 3636 426426
YesYes 191191 6262 253253
581581 9898 679679
Pine et al. 1998, 2001, 2002
![Page 7: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/7.jpg)
Any Adolescent Anxiety Disorder & Any Adult Mood/Anxiety Disorder
Disorder as Adults?Disorder as Adults?
Disorder asDisorder as
Adolescents?Adolescents?NoNo YesYes
NoNo 390390 3636 426426
YesYes 191191 6262 253253
581581 9898 679679
Pine et al. 1998, 2001, 2002
![Page 8: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/8.jpg)
Any Adolescent Anxiety Disorder & Any Adult Mood/Anxiety Disorder
Disorder as Adults?Disorder as Adults?
Disorder asDisorder as
Adolescents?Adolescents?NoNo YesYes
NoNo 390390 3636 426426
YesYes 191191 6262 253253
581581 9898 679679
Pine et al. 1998, 2001, 2002
![Page 9: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/9.jpg)
Any Adolescent Anxiety Disorder & Any Adult Mood/Anxiety Disorder
Disorder as Adults?Disorder as Adults?
Disorder asDisorder as
Adolescents?Adolescents?NoNo YesYes
NoNo 390390 3636 426426
YesYes 191191 6262 253253
581581 9898 679679
Pine et al. 1998, 2001, 2002
![Page 10: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/10.jpg)
Length of Treatment (Pine 2002)
Chronic anxiety not inevitableChronic anxiety not inevitable Stable children without symptoms need a Stable children without symptoms need a
trial off of an SSRItrial off of an SSRI Applies more to anxiety than MDDApplies more to anxiety than MDD Questions on safety, when and who to treatQuestions on safety, when and who to treat
![Page 11: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/11.jpg)
Treatment of Pediatric Anxiety
SSRIs & BeyondSSRIs & Beyond
![Page 12: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/12.jpg)
Specific Agents
SSRIs/SSNRIsSSRIs/SSNRIs
BenzodiazepinesBenzodiazepines
TCAsTCAs
PsychostimulantsPsychostimulants
SNRIsSNRIs
Antipsychotics (?)Antipsychotics (?)
Anticonvulsants (?)Anticonvulsants (?)
![Page 13: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/13.jpg)
Specific Agents
SSRIsSSRIs/SSNRIs/SSNRIs
BenzodiazepinesBenzodiazepines
TCAsTCAs
PsychostimulantsPsychostimulants
SNRIsSNRIs
Antipsychotics (?)Antipsychotics (?)
Anticonvulsants (?)Anticonvulsants (?)
![Page 14: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/14.jpg)
SSRIs & Efficacy in Pediatric Populations
SAD/GAD/Soph
OCD
MDD
![Page 15: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/15.jpg)
SSRIs and Pediatric Anxiety: Efficacy
Evidence for efficacy in GAD, social anxiety, Evidence for efficacy in GAD, social anxiety, separation anxiety disorderseparation anxiety disorder
Particularly good evidence for fluvoxamine, Particularly good evidence for fluvoxamine, fluoxetine, paroxetine, sertraline fluoxetine, paroxetine, sertraline
CBTCBT
![Page 16: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/16.jpg)
![Page 17: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/17.jpg)
Rates of Improvement
StudyStudy DifferenceDifference PBOPBO SSRISSRI
RUPP Anxiety Study (2001)RUPP Anxiety Study (2001) 47%47% 29%29% 76%76%
Birmaher et al. (2003)Birmaher et al. (2003) 25%25% 36%36% 61%61%
Rynn et al. (2001)Rynn et al. (2001) 80%80% 10%10% 90%90%
Wagner et al. (2004)Wagner et al. (2004) 40%40% 38%38% 78%78%
Rynn et al. (2006)Rynn et al. (2006) 12%12% 24%24% 36%36%
TotalTotal 30%30% 31%31% 61%61%
Meta-Analysis: Rates of Improvement
NNT=3.3
![Page 18: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/18.jpg)
Walkup J et al. N Engl J Med 2008;10.1056/NEJMoa0804633
The CAMS Study
![Page 19: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/19.jpg)
SSRIs and Pediatric OCD
Five SSRIs have been shown to workFive SSRIs have been shown to work No robust differences among the fiveNo robust differences among the five FDA approval:FDA approval:
Prozac, Luvox, ZoloftProzac, Luvox, Zoloft CBT vs. SSRICBT vs. SSRI
Strong site differencesStrong site differences Benefit for combination?Benefit for combination? Data in adultsData in adults
![Page 20: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/20.jpg)
Copyright restrictions may apply.
The Pediatric OCD Treatment Study (POTS) Team, JAMA 2004;292:1969-1976.
Weekly Adjusted Intent-to-Treat CY-BOCS Score, by Treatment Group
![Page 21: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/21.jpg)
SSRIs and Controversy
![Page 22: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/22.jpg)
SSRIs and Controversy
Biased reporting of data for efficacyBiased reporting of data for efficacy
![Page 23: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/23.jpg)
Biased Reporting in Adult Antidepressant TrialsTurner et al. NEJM 2008
0
0 .0 50 .1
0 .1 50 .2
0 .2 50 .3
0 .3 50 .4
0 .4 5
E ffe c t S ize (H e d g e 's g )
A ll D a ta
P u b lish e d D a taO n lyU n p u b lish e dD a ta O n ly
Bias in Publication Bias in Magnitude of Clinical Effect
![Page 24: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/24.jpg)
SSRIs and Controversy
Concerns about suicidal ideationConcerns about suicidal ideation
![Page 25: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/25.jpg)
FDA Analysis from December, 2006
Antidepressants and Thoughts About Suicide
![Page 26: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/26.jpg)
SSRIs and Controversy
FDA & Black BoxFDA & Black Box
![Page 27: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/27.jpg)
Bottom Line of the SSRIs SSRIs are very effective in the treatment of SSRIs are very effective in the treatment of
pediatric anxiety.pediatric anxiety. Of the SSRIs, only fluoxetine has been Of the SSRIs, only fluoxetine has been
clearly shown to be effective in pediatric clearly shown to be effective in pediatric MDD. MDD.
Increased risk of suicidality with SSRI Increased risk of suicidality with SSRI treatment is real, but the magnitude of the treatment is real, but the magnitude of the effect is small.effect is small.
![Page 28: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/28.jpg)
Mechanism of beneficial and adverse SSRI Mechanism of beneficial and adverse SSRI effects in a developmental contexteffects in a developmental context Studies in animal models Studies in animal models
Novel treatment approachesNovel treatment approaches The perspective of neuroscienceThe perspective of neuroscience
Attention RetrainingAttention RetrainingExtinctionExtinction
Future Directions
![Page 29: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/29.jpg)
Mechanism of beneficial and adverse SSRI Mechanism of beneficial and adverse SSRI effects in a developmental contexteffects in a developmental context Studies in animal models Studies in animal models
Novel treatment approachesNovel treatment approaches The perspective of neuroscienceThe perspective of neuroscience
Attention RetrainingAttention RetrainingExtinctionExtinction
Future Directions
![Page 30: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/30.jpg)
Development, Anxiety, & 5-HT1a RGross et al. Nature 2002
5-HT1a receptor must be present pre-adolescence to “rescue” anxious
phenotype.
The effect of SSRIs on developing nervous system is not fully understood
Ansorge et al (2004)Science
![Page 31: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/31.jpg)
Mechanism of beneficial and adverse SSRI Mechanism of beneficial and adverse SSRI effects in a developmental contexteffects in a developmental context Studies in animal models Studies in animal models
Novel treatment approachesNovel treatment approaches The perspective of neuroscienceThe perspective of neuroscience
Attention RetrainingAttention RetrainingExtinctionExtinction
Future Directions
![Page 32: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/32.jpg)
VISUALVISUALCORTEXCORTEX
AMYGDALAAMYGDALA
HEART RATE
BLOOD PRESSUREBLOOD PRESSURE MUSCLEMUSCLE
VISUAL THALAMUS
LeDoux. LeDoux. Sci AmSci Am. 1994;270:50.. 1994;270:50.
![Page 33: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/33.jpg)
Visual probe task with emotional faces
14 ms
*
17-1250 ms
Vigilance for threat = Faster RTs to probes replacing threat vs. neutral faces
Bar-Haim et al. (2007)
Mogg & Bradley
+
500 ms
![Page 34: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/34.jpg)
AMYGDALAAMYGDALA
The circuitry of attention bias in pediatric GAD
![Page 35: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/35.jpg)
Attention, PFC-Amygdala-Circuitry, and Pediatric Anxiety
Prolonged Threat: PFC regulates anxiety
Monk et al. 2006, 2008
Brief Subliminal Threat: Amygdala instantiates anxiety
![Page 36: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/36.jpg)
Attention Retraining Therapy
0
2
4
6
8
10
12
Train to Neutral Train to AngryA
nxi
ety
Sco
re
Eldara, Ricona, & Bar-Haim in pressTraining of Attention
Altered Response to Stress
![Page 37: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/37.jpg)
![Page 38: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/38.jpg)
Any Adolescent Anxiety Disorder & Any Adult Mood/Anxiety Disorder
Disorder as Adults?Disorder as Adults?
Disorder asDisorder as
Adolescents?Adolescents?NoNo YesYes
NoNo 390390 3636 426426
YesYes 191191 6262 253253
581581 9898 679679
Pine et al. 1998, 2001, 2002
![Page 39: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/39.jpg)
Ressler & Davis 2003
Ressler & Davis 2003
![Page 40: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/40.jpg)
Ressler & Davis 2003
Extinction: Not forgetting but new learning
Anxiety disorders as problems in new learning
Ressler & Davis 2003
![Page 41: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/41.jpg)
Ressler & Davis 2003
NMDA manipulation
Ressler & Davis 2003NMDA manipulations?
![Page 42: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/42.jpg)
Copyright restrictions may apply.
Ressler, K. J. et al. Arch Gen Psychiatry 2004;61:1136-1144.
Acrophobia within the virtual environment is improved with D-cycloserine
![Page 43: Pediatric Anxiety: Current and Future Approaches to Therapeutics Daniel S. Pine, MD.](https://reader036.fdocuments.in/reader036/viewer/2022062323/56649d9f5503460f94a89575/html5/thumbnails/43.jpg)
Conclusions
Classifying Anxiety & MDDClassifying Anxiety & MDD
Efficacy of SSRIs, other agentsEfficacy of SSRIs, other agents
Going beyond SSRIsGoing beyond SSRIs